We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

473 hedge funds and large institutions have $22.5B invested in Alnylam Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 165 increasing their positions, 154 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

7% more repeat investments, than reductions

Existing positions increased: 165 | Existing positions reduced: 154

0% less funds holding

Funds holding: 475 → 473 (-2)

1.1% less ownership

Funds ownership: 96.33% → 95.23% (-1.1%)

11% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 56

20% less capital inflows, than outflows

Capital inflows: $765M | Capital outflows: $961M

26% less call options, than puts

Call options by funds: $119M | Put options by funds: $162M

Holders
473
Holders Change
-2
Holders Change %
-0.42%
% of All Funds
7.41%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
50
Increased
165
Reduced
154
Closed
56
Calls
$119​M
Puts
$162​M
Net Calls
-⁠$42.2​M
Net Calls Change
-⁠$77​M

ALNY Hedge Fund Activity: Q2 2023 in Review

473 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2023, worth a combined $22.5B — down 6% from $24B a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of ALNY and 50 opened new positions — a net loss of 6 holders — while 154 trimmed existing stakes and 165 added.

The largest buyer was Capital International Investors, adding an estimated $129M. The largest seller was Norges Bank, cutting an estimated $162M.

  • 473 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2023, down from 475 in Q1 2023.
  • Funds reported $22.5B of Alnylam Pharmaceuticals stock for Q2 2023, down 6% quarter-over-quarter.
  • 50 funds opened new Alnylam Pharmaceuticals positions in Q2 2023 and 56 closed out, a net change of -6 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q2 2023 was Capital International Investors, an estimated $129M added.
  • The largest Alnylam Pharmaceuticals seller in Q2 2023 was Norges Bank, an estimated $162M sold.

Based on aggregated 13F filings for Q2 2023.